Quoin Pharma reports Q4/FY2023 net loss $8.7M; cash runway to H2 2025; positive QRX003 data

Quoin Pharmaceuticals, Ltd.

Net loss Q4 2023 $2.0M (flat YoY); FY2023 $8.7M vs $9.4M in 2022.
Cash & equivalents $10.7M as of Dec 31, 2023; plus $6.5M March 5 offering and $8M ELOC (pending shareholder approval).
Positive initial data from first 6 evaluable subjects: 5/6 had negligible/absent itch; all 6 showed skin score improvement.
No safety concerns reported in either ongoing Netherton Syndrome study; enrollment age lowered to 14+.
Expects cash runway to extend into H2 2025.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Quoin Pharmaceuticals, Ltd. reported the quarter and year ended December 31, 2023 results: net income Net loss for the quarter ended December 31, 2023 was approximately $2.0 million compared to approximately $2.0 million f.

Period: the quarter and year ended December 31, 2023
Net income: Net loss for the quarter ended December 31, 2023 was approximately $2.0 million compared to approximately $2.0 million f
Result: reported results

Exact text from the filing

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today provides a business update and announces financial results for the quarter and year ended December 31, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Quoin Pharmaceuticals, Ltd. filing history →

Source: SEC EDGAR

accession 0001104659-24-033990

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.